FRESH-PEF73342-en
Study of the conditions of use of golimumab and its impact, in current practice, in patients with chronic inflammatory rheumatism.
GO-PRACTICE
| Name | Country code |
|---|---|
| France | fr |
['Clinical data','Participant-reported health data','Biological data']
Individuals
| Topic | Vocabulary |
|---|---|
| Rheumatology | health theme |
| Inflammatory arthropathies | cim-11 |
{
"level_sex_clusion_I": [
{
"value": "Male",
"concept": {
"vocab": "MeSH",
"vocabURI": "http:\/\/id.nlm.nih.gov\/mesh\/D008297"
}
},
{
"value": "Female",
"concept": {
"vocab": "MeSH",
"vocabURI": "http:\/\/id.nlm.nih.gov\/mesh\/D005260"
}
}
],
"level_age_clusion_I": [
{
"value": "Young Adult (19 to 24 years)",
"concept": {
"vocab": "MeSH",
"vocabURI": "http:\/\/id.nlm.nih.gov\/mesh\/D055815"
}
},
{
"value": "Adult (25 to 44 years)",
"concept": {
"vocab": "MeSH",
"vocabURI": "http:\/\/id.nlm.nih.gov\/mesh\/D000328"
}
},
{
"value": "Middle Aged (45 to 64 years)",
"concept": {
"vocab": "MeSH",
"vocabURI": "http:\/\/id.nlm.nih.gov\/mesh\/D008875"
}
},
{
"value": "Aged (65 to 79 years)",
"concept": {
"vocab": "MeSH",
"vocabURI": "http:\/\/id.nlm.nih.gov\/mesh\/D000368"
}
},
{
"value": "Aged, 80 and over (80 years and more)",
"concept": {
"vocab": "MeSH",
"vocabURI": "http:\/\/id.nlm.nih.gov\/mesh\/D000369"
}
}
],
"level_type_clusion_I": [
"Patients population"
],
"level_type_clusion_other": "",
"clusion_I": "Inclusion: 1. Patients aged 18 years or older. 2. Patients who gave oral consent to participate after receiving oral and written information about the study. 3. Patients with a diagnosis of chronic inflammatory rheumatism. 4. Patients with an initial hospital prescription of golimumab but not yet having initiated treatment with golimumab. 5. Patients able to understand and complete the self-evaluation questionnaires ",
"clusion_E": "1. Patients previously treated with golimumab and discontinuing treatment prior to inclusion.2. Patients who participated in previous golimumab trials3. Patients who had already begun treatment with golimumab prior to inclusion and were receiving treatment at the time of inclusion.4. Patients with pathologies or conditions that, according to the investigator, would limit the patient's ability to participate fully in the study or to meet all the requirements of the study;"
}
| Name |
|---|
| Najat;GOUYETTE |
| Laurie;LEVY-BACHELOT |
| Name | Role |
|---|---|
| MSD FRANCE | sponsor |
| Name |
|---|
| MSD FRANCE |
['Through independent healthcare practitioners']
['{"concept":{"vocabURI":"Other","vocab":"CESSDA"},"value":"Other"}']
Access not yet planned
Observational Study
{"value":"To be defined","extLink":[]}
| Name | |
|---|---|
| Laurie;LEVY-BACHELOT | laurie.levy-bachelot@msd.com |
FRESH-PEF73342-en
| Name | Affiliation |
|---|---|
| Laurie LEVY-BACHELOT | MSD FRANCE |